Observational Study of NovoNorm® in Subjects With Diabetes

Completed

• Conditions: Diabetes; Diabetes Mellitus, Type 2
• Interventions: Drug: repaglinide

• Registration Number: NCT01498913
• Lead Sponsor: Novo Nordisk A/S

Brief Summary

This study is conducted in Asia. The aim of this study is to review the safety and efficacy of Novonorm® (repaglinide) in post-marketing use.

Detailed Description

Not available

Study Timeline

• Study Start: 2001-08-30
• Primary Completion: 2005-03-25
• Study Completion: 2005-03-25
• Study First Submitted: 2011-12-21
• Study First Submitted QC: 2011-12-21
• Study First Posted: 2011-12-26
• Status Verified: 2017-02
• Last Update Submitted: 2017-02-17
• Last Update Posted: 2017-02-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 5841

Inclusion Criteria

• Type 2 diabetes

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Repaglinide	repaglinide	-

Primary Outcome Measures

Name	Time	Method
HbA1c (glycosylated haemoglobin)
2 hours postprandial blood glucose (2-hr PPBG)
Fasting blood glucose (FBG)
Body weight

Secondary Outcome Measures

Name	Time	Method
Adverse events

Trial Locations

Locations (1)

Novo Nordisk Investigational Site; 🇰🇷 Seoul, Korea, Republic of